Effect of the somatostatin analog SMS 201-995 on GH- and PRL-secretion in patients with acromegaly

1984 ◽  
Vol 104 (4_Supplb) ◽  
pp. S30-S31 ◽  
Author(s):  
G. MAYER ◽  
H. TILLIL
Keyword(s):  
Somatostatin Analog

Treatment of therapy-resistant acromegaly with the somatostatin analog SMS 201–995

1987 ◽  
Vol 116 (3_Suppl) ◽  
pp. S202
Author(s):  
K. VON WERDER ◽  
J. SCHOPOHL ◽  
M. LOSA ◽  
J. ALBA LOPEZ ◽  
O.A. MÜLLER ◽  
...  
Keyword(s):  
Somatostatin Analog

Long-term effectiveness of the somatostatin analog SMS 201-995 in the treatment of acromegaly

1988 ◽  
Vol 117 (4_Suppl) ◽  
pp. S107 ◽  
Author(s):  
U. PLÖCKINGER ◽  
H.-J. QUABBE
Keyword(s):  
Somatostatin Analog

Growth hormone and insulin signalling after acute GH exposure in patients with controlled acromegaly: impact of surgery versus somatostatin analog treatment

2016 ◽  
Author(s):  
Jakob Dal ◽  
Hoyer Katrine Lundby ◽  
Steen B Pedersen ◽  
Nils Magnusson ◽  
Peter Bjerrring ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Insulin Signalling ◽  
Somatostatin Analog

Metastatic insulinoma managed with lutetium (177LU) and somatostatin analog

2020 ◽  
Author(s):  
Mehmet Sözen ◽  
Zeynep Canturk ◽  
Berrin Cetinarslan ◽  
Alev Selek ◽  
Emre Gezer
Keyword(s):  
Somatostatin Analog

scholarly journals A new 68Ga-labeled somatostatin analog containing two iodo-amino acids for dual somatostatin receptor subtype 2 and 5 targeting

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Rosalba Mansi ◽  
Karim Abid ◽  
Guillaume P. Nicolas ◽  
Luigi Del Pozzo ◽  
Eric Grouzmann ◽  
...  
Keyword(s):  
Amino Acids ◽  
Somatostatin Receptor ◽  
Somatostatin Analog ◽  
Receptor Subtype ◽  
Somatostatin Receptor Subtype 2

scholarly journals A Machine Learning Decision Support System (DSS) for Neuroendocrine Tumor Patients Treated with Somatostatin Analog (SSA) Therapy

Diagnostics ◽  
2021 ◽  
Vol 11 (5) ◽  
pp. 804
Author(s):  
Jasminka Hasic Telalovic ◽  
Serena Pillozzi ◽  
Rachele Fabbri ◽  
Alice Laffi ◽  
Daniele Lavacchi ◽  
...  
Keyword(s):  
Machine Learning ◽  
Single Agent ◽  
Predictive Biomarkers ◽  
Progression Free Survival ◽  
Primary Site ◽  
Somatostatin Analog ◽  
Support Vector ◽  
Classification Models ◽  
First Line Therapy ◽  
Bayes Algorithm

The application of machine learning (ML) techniques could facilitate the identification of predictive biomarkers of somatostatin analog (SSA) efficacy in patients with neuroendocrine tumors (NETs). We collected data from 74 patients with a pancreatic or gastrointestinal NET who received SSA as first-line therapy. We developed three classification models to predict whether the patient would experience a progressive disease (PD) after 12 or 18 months based on clinic-pathological factors at the baseline. The dataset included 70 samples and 15 features. We initially developed three classification models with accuracy ranging from 55% to 70%. We then compared ten different ML algorithms. In all but one case, the performance of the Multinomial Naïve Bayes algorithm (80%) was the highest. The support vector machine classifier (SVC) had a higher performance for the recall metric of the progression-free outcome (97% vs. 94%). Overall, for the first time, we documented that the factors that mainly influenced progression-free survival (PFS) included age, the number of metastatic sites and the primary site. In addition, the following factors were also isolated as important: adverse events G3–G4, sex, Ki67, metastatic site (liver), functioning NET, the primary site and the stage. In patients with advanced NETs, ML provides a predictive model that could potentially be used to differentiate prognostic groups and to identify patients for whom SSA therapy as a single agent may not be sufficient to achieve a long-lasting PFS.

Preoperative Treatment of Acromegaly with Long-Acting Somatostatin Analog SMS 201-995: Shrinkage of Invasive Pituitary Macroadenomas and Improved Surgical Remission Rate*

1988 ◽  
Vol 67 (5) ◽  
pp. 1040-1048 ◽  
Author(s):  
ARIEL L. BARKAN ◽  
RICARDO V. LLOYD ◽  
WILLIAM F. CHANDLER ◽  
MALCOLM K. HATFIELD ◽  
STEPHEN S. GEBARSKI ◽  
...  
Keyword(s):  
Remission Rate ◽  
Somatostatin Analog ◽  
Preoperative Treatment ◽  
Long Acting ◽  
Pituitary Macroadenomas

scholarly journals Cotreatment with Pegvisomant and a Somatostatin Analog (SA) in SA-Responsive Acromegalic Patients

2011 ◽  
Vol 96 (8) ◽  
pp. 2405-2413 ◽  
Author(s):  
Michael Madsen ◽  
Per L. Poulsen ◽  
Hans Ørskov ◽  
Niels Møller ◽  
Jens O. L. Jørgensen
Keyword(s):  
Glucose Tolerance ◽  
Low Dose ◽  
Tolerance Test ◽  
Somatostatin Analog ◽  
Oral Glucose ◽  
Tertiary Referral Center ◽  
Elevated Liver Enzymes ◽  
Igf I ◽  
Insufficient Response

Abstract Context: Cotreatment of acromegaly with pegvisomant and a somatostatin analog (SA) has proven feasible. Previous studies in the field have focused on patients with an insufficient response to SA monotherapy in whom pegvisomant was added without changing the SA dose. Objective: The objective of the study was to study whether patients sufficiently controlled on SA monotherapy can be transferred to combination therapy with low-dose pegvisomant and a reduced SA dose. Design: Eighteen acromegalic patients well controlled on SA monotherapy, mean ± se aged 54 ± 3 yr, were randomized in a parallel study over 24 wk to unchanged SA monotherapy or cotreatment with pegvisomant (15–30 mg twice a week) and SA (half the usual dosage). Setting: This was an investigator-initiated study in a single tertiary referral center. Main Outcome Measures: Glucose tolerance, substrate metabolism, insulin sensitivity, body composition, and quality of life were measured. Results: Median pegvisomant dose was 52.5 mg/wk (range 30–60). IGF-I (micrograms per liter) was comparable both at baseline (P = 0.88) and after 24 wk of treatment (P = 0.48). The change in IGF-I between baseline and wk 24 also did not differ between groups (P = 0.15). Apart from increased peak insulin levels during the oral glucose tolerance test in the cotreatment group, no substantial differences between the two groups were detected. Moderately elevated liver enzymes were found in 17% of the patients on pegvisomant therapy. Conclusion: Acromegalic patients well controlled on SA monotherapy can maintain safe IGF-I levels during 24 wk of cotreatment with low-dose pegvisomant and a 50% reduced SA dose. This treatment modality, however, does not seem to provide significant benefits for the patients.

Evaluation of a radiolabeled somatostatin analog (I-123 octreotide) in the detection and localization of carcinoid and islet cell tumors.

Radiology ◽  
1993 ◽  
Vol 187 (1) ◽  
pp. 129-133 ◽  
Author(s):  
L K Kvols ◽  
M L Brown ◽  
M K O'Connor ◽  
J C Hung ◽  
R J Hayostek ◽  
...  
Keyword(s):  
Islet Cell ◽  
Somatostatin Analog ◽  
Islet Cell Tumors ◽  
Radiolabeled Somatostatin Analog ◽  
Detection And Localization
Sign in / Sign up

Export Citation Format

Share Document